We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.46B
AUM Growth
-$732M
Cap. Flow
-$476M
Cap. Flow %
-10.67%
Top 10 Hldgs %
48.58%
Holding
171
New
10
Increased
26
Reduced
81
Closed
23

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$53M
2
BEAM icon
Beam Therapeutics
BEAM
+$23M
3
SYK icon
Stryker
SYK
+$17.7M
4
ABBV icon
AbbVie
ABBV
+$17.5M
5
BAX icon
Baxter International
BAX
+$14.9M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$204M
2
ARVN icon
Arvinas
ARVN
+$45.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$34.7M
4
VRNA
Verona Pharma
VRNA
+$30.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Miscellaneous 0.11%
3 Technology 0.01%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
151
Autolus Therapeutics
AUTL
$596M
– –
-41,500
Closed -$97.5K
BPMC
152
DELISTED
Blueprint Medicines
BPMC
– –
-3,200
Closed -$279K
CRL icon
153
Charles River Laboratories
CRL
$13.8B
– –
-50,327
Closed -$9.29M
DNLI icon
154
Denali Therapeutics
DNLI
$3.56B
– –
-15,700
Closed -$320K
FATE icon
155
Fate Therapeutics
FATE
$297M
– –
-4,839,779
Closed -$7.99M
GOOG icon
156
Alphabet (Google) Class C
GOOG
$4.1T
– –
-6,000
Closed -$1.14M
KNSA icon
157
Kiniksa Pharmaceuticals
KNSA
$6.08B
– –
-8,100
Closed -$160K
KURA icon
158
Kura Oncology
KURA
$1.18B
– –
-13,600
Closed -$118K
MRNA icon
159
CALL
Moderna
MRNA
$58.1B
– –
-150
Closed -$110K
NRIX icon
160
Nurix Therapeutics
NRIX
$2.71B
– –
-8,000
Closed -$151K
OMCL icon
161
Omnicell
OMCL
$1.57B
– –
-94,740
Closed -$4.22M
RARE icon
162
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-4,000
Closed -$168K
ROIV icon
163
Roivant Sciences
ROIV
$25.2B
– –
-24,000
Closed -$284K
SAGE
164
DELISTED
Sage Therapeutics
SAGE
– –
-4,460,693
Closed -$24.2M
TERN
165
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,061,753
Closed -$5.88M
TNDM icon
166
Tandem Diabetes Care
TNDM
$1.38B
– –
-782,456
Closed -$28.2M
VCYT icon
167
Veracyte
VCYT
$3.42B
– –
-3,600
Closed -$143K
VKTX icon
168
Viking Therapeutics
VKTX
$4.07B
– –
-12,939
Closed -$521K
XENE icon
169
Xenon Pharmaceuticals
XENE
$5.79B
– –
-8,200
Closed -$321K
ACCD
170
DELISTED
Accolade Inc
ACCD
– –
-615,509
Closed -$2.11M
ITCI
171
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-2,440,240
Closed -$204M
3 4 5 6
7

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q1 2025 Portfolio in Review

As of Q1 2025, Bellevue Group held 171 positions worth $4.46B, down 14% from $5.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $476M in Q1 2025, closing 23 positions and reducing 81 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $204M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Bellevue Group opened a new position in Akero Therapeutics worth $50.6M.

  • Bellevue Group's largest Q1 2025 buy was Akero Therapeutics: 1,250,666 shares worth $50.6M.
  • Bellevue Group added most to Beam Therapeutics in Q1 2025, an estimated $23M increase.
  • Bellevue Group's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $34.7M.
  • Bellevue Group fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $204M.
  • Bellevue Group's ten largest holdings make up 49% of its $4.46B portfolio in Q1 2025.
  • Bellevue Group opened 10 new positions and closed 23 in Q1 2025.
  • Bellevue Group's portfolio value fell 14% quarter-over-quarter to $4.46B.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.